Argent BioPharma Limited (RGT.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Roby Reuven Zomer | Co-Founder, CEO & Chairman | 417.06k | -- | 1980 |
| Mr. Igor Bluvstein | Chief Financial Officer | -- | -- | 1982 |
| Shachar Shimony | Group General Counsel | -- | -- | -- |
| Mr. Amir Polak | Chief Pharmaceutical Development Officer | -- | -- | -- |
| Ms. Sabina Suljakovic | Chief Quality and Commercial Officer | -- | -- | -- |
| Dr. Nadya Lisovoder | Chief Medical Officer | -- | -- | -- |
| Ms. Sasha Friedman | Deputy CEO | -- | -- | -- |
| Yair Tal | Chief Information Security Officer | -- | -- | -- |
| Mr. Rowan Harland | Company Secretary | -- | -- | -- |
| Ana Arhar Oblak | Group Financial Controller | -- | -- | -- |
Argent BioPharma Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company's principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment. The company has collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Corporate Governance
Upcoming Events
July 27, 2025 at 11:02 PM UTC - July 31, 2025 at 11:02 PM UTC
Argent BioPharma Limited Earnings Date
Recent Events
Recent Events Information Not Available